Home » SCHERING-PLOUGH TO DEVELOP CENTOCOR COMPOUND
SCHERING-PLOUGH TO DEVELOP CENTOCOR COMPOUND
Schering-Plough Corp. (SGP.N: Quote, Profile, Research) said on Tuesday it will develop Centocor Inc.'s treatment for rheumatoid arthritis and other inflammatory diseases. The drugmaker said it will take a third-quarter charge of $125 million related to the agreement with Centocor, its development partner since 1988. Centocor is a Johnson & Johnson (JNJ.N: Quote, Profile, Research) subsidiary.
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May